115 related articles for article (PubMed ID: 33797637)
21. Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer.
Liu Z; Lu T; Li J; Wang L; Xu K; Dang Q; Liu L; Guo C; Jiao D; Sun Z; Han X
Front Immunol; 2021; 12():702594. PubMed ID: 34394098
[TBL] [Abstract][Full Text] [Related]
22. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection.
Kim C; Kim WR; Kim KY; Chon HJ; Beom SH; Kim H; Jung M; Shin SJ; Kim NK; Ahn JB
Clin Colorectal Cancer; 2018 Sep; 17(3):e513-e518. PubMed ID: 29661621
[TBL] [Abstract][Full Text] [Related]
23. Early detection of recurrence after curative resection for colorectal cancer - obstacles when using soluble biomarkers?
Nielsen HJ; Jess P; Aldulaymi BH; Jørgensen LN; Laurberg S; Nielsen KT; Madsen MR; Brünner N; Christensen IJ
Scand J Gastroenterol; 2013 Mar; 48(3):326-33. PubMed ID: 23324066
[TBL] [Abstract][Full Text] [Related]
24. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
[TBL] [Abstract][Full Text] [Related]
25. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.
Yuan D; Li K; Zhu K; Yan R; Dang C
Cancer Biol Ther; 2015; 16(2):268-75. PubMed ID: 25629978
[TBL] [Abstract][Full Text] [Related]
26. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
Izumi K; Mizokami A; Lin HP; Ho HM; Iwamoto H; Maolake A; Natsagdorj A; Kitagawa Y; Kadono Y; Miyamoto H; Huang CK; Namiki M; Lin WJ
Oncotarget; 2016 Feb; 7(7):8389-98. PubMed ID: 26701731
[TBL] [Abstract][Full Text] [Related]
27. CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease.
Matsuda S; Kotani T; Kuwabara H; Suzuka T; Kiboshi T; Fukui K; Ishida T; Fujiki Y; Shiba H; Hata K; Shoda T; Hirose Y; Takeuchi T
Rheumatology (Oxford); 2021 Oct; 60(10):4643-4653. PubMed ID: 33493350
[TBL] [Abstract][Full Text] [Related]
28. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.
Chatla C; Jhala NC; Katkoori VR; Alexander D; Meleth S; Grizzle WE; Manne U
Cancer Biomark; 2005; 1(4-5):241-50. PubMed ID: 17192048
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection.
Tsai HL; Chu KS; Huang YH; Su YC; Wu JY; Kuo CH; Chen CW; Wang JY
J Surg Oncol; 2009 Dec; 100(8):736-43. PubMed ID: 19757443
[TBL] [Abstract][Full Text] [Related]
30. High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer.
Heiskala M; Leidenius M; Joensuu K; Heikkilä P
Virchows Arch; 2019 Jan; 474(1):3-12. PubMed ID: 30368555
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection.
Tsai HL; Yang IP; Huang CW; Ma CJ; Kuo CH; Lu CY; Juo SH; Wang JY
Transl Res; 2013 Oct; 162(4):258-68. PubMed ID: 23933284
[TBL] [Abstract][Full Text] [Related]
32. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer.
Matsumura T; Sugimachi K; Iinuma H; Takahashi Y; Kurashige J; Sawada G; Ueda M; Uchi R; Ueo H; Takano Y; Shinden Y; Eguchi H; Yamamoto H; Doki Y; Mori M; Ochiya T; Mimori K
Br J Cancer; 2015 Jul; 113(2):275-81. PubMed ID: 26057451
[TBL] [Abstract][Full Text] [Related]
33. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
Tsukamoto M; Iinuma H; Yagi T; Matsuda K; Hashiguchi Y
Oncology; 2017; 92(6):360-370. PubMed ID: 28376502
[TBL] [Abstract][Full Text] [Related]
34. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a lipogenic genes panel for diagnosis and recurrence of colorectal cancer.
Gharib E; Nasrinasrabadi P; Zali MR
PLoS One; 2020; 15(3):e0229864. PubMed ID: 32155177
[TBL] [Abstract][Full Text] [Related]
36. Jagged-1 Expression Level Is Correlated With Recurrence of Stage III Colorectal Cancer in Patients Receiving Adjuvant Chemotherapy.
Kim HB; Lee SB; Kim SJ; Lee HJ; Park SG
Anticancer Res; 2021 Sep; 41(9):4645-4650. PubMed ID: 34475093
[TBL] [Abstract][Full Text] [Related]
37. Optimal Surveillance Protocols After Curative Resection in Patients With Stage IV Colorectal Cancer: A Multicenter Retrospective Study.
Kishiki T; Lapin B; Matsuoka H; Watanabe T; Takayasu K; Kojima K; Sugihara K; Masaki T
Dis Colon Rectum; 2018 Jan; 61(1):51-57. PubMed ID: 29215480
[TBL] [Abstract][Full Text] [Related]
38. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
39. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
40. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
